Hydrogels based on functionalized polysaccharides

Patent metadata

Field	Value
Publication number	US-12162995-B2
Application number	US-202217991608-A
Country	US
Kind code	B2
Filing date	Nov 21, 2022
Priority date	Sep 14, 2016
Publication date	Dec 10, 2024
Grant date	Dec 10, 2024

Abstract

The present invention relates to functionalized hydrogel networks grafted with at least one moiety for use in numerous fields, from cosmetics to surgery and medicine.

First claim

The invention claimed is:

1. A composition comprising:
a. a functionalized hydrogel based on an anionic polysaccharide grafted with at least one moiety, wherein the moiety is a synthetic biocompatible polymer grafted on at least one hydroxyl group of said anionic polysaccharide;
b. a second component selected from cells, proteins, nucleic acids, and other molecules; and
c. an active principle or bioactive agent,
wherein said functionalized hydrogel is in the form of a microsphere,
wherein said second component is encapsulated within the functionalized hydrogel microsphere,
wherein the active principle or bioactive agent is linked to the microsphere through non-covalent or covalent interactions,
wherein the synthetic biocompatible polymer is a polyethylene glycol (PEG) or PEG derivative or a polyethyleneimine, and
wherein the moiety is grafted on hydroxyl groups of said anionic polysaccharide through a carbamate bond.

2. The composition of claim 1 , wherein the anionic polysaccharide comprises one or more carboxylic acid functional groups.

3. The composition of claim 1 , wherein the anionic polysaccharide is selected from the group consisting of alginate, hyaluronan, galacturonan, and a salt thereof.

4. The composition of claim 1 , wherein the degree of grafting of the moiety on hydroxyl groups of said anionic polysaccharide is comprised between 5 and 30 mol %.

5. The composition of claim 1 , wherein the PEG or PEG derivative is selected from the group consisting of a linear PEG, a derivative of linear PEG, a multi-arm PEG, a derivative of multi-arm PEG, and a derivative of a linear or multi-arm PEG presenting terminal reactive functionalities.

6. The composition of claim 5 , wherein the PEG, or a derivative thereof, is a heterobifunctional PEG of formula I, II and/or III:

wherein,
n=8 to 50;
R 1 is independently selected from NH 2 , N 3 , OH, and C 1-6 alkyl-CO 2 H;
R 2 is independently selected from (CH 2 ) p SH, with p=2 to 10,

with q=2 to 5, and

with m=2 to 10; and
R 3 is independently selected from

7. The composition of claim 1 , wherein the functionalized hydrogel is selected from Alg-PEG-a I and Alg-PEG-a II.

8. The composition of claim 1 , wherein the second component is a cell from human or animal origin selected from keratinocytes, fibroblasts, osteocytes, chondrocytes, urocytes, stem cells, endothelial cells, pancreatic cells, liver cells, and neural cells.

9. The composition of claim 1 , wherein the active principle or bioactive agent is an anti-inflammatory agent.

10. The composition of claim 9 , wherein the anti-inflammatory agent is selected from curcumin and ketoprofen.

11. The composition of claim 1 , wherein the synthetic biocompatible polymer is functionalized with the active principle or bioactive agent.

12. The composition of claim 5 , wherein the functionalized hydrogel is a PEG or a PEG derivative-grafted alginate, wherein the PEG or PEG derivative is further functionalized with the active principle or bioactive agent.

13. The composition of claim 12 , wherein the PEG or PEG derivative is functionalized with the active principle or bioactive agent using an ester, an amide or a hydrazine linkage or a disulfide bridge.

14. The composition of claim 13 , wherein the functionalized hydrogel is alginate grafted with PEG, wherein PEG is further functionalized with ketoprofen using an ester or an amide linkage.

15. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

16. A method of treating and/or preventing a disease or disorder in a human or animal patient, the method comprising implanting or transplanting into a human or animal patient the composition according to claim 1 .

17. The method according to claim 16 , wherein the composition is implanted or transplanted as a coating for organs or for biomedical articles.

18. The method according to claim 16 , wherein the composition serves as a carrier for the controlled delivery of the second component after transplantation.

19. A biomedical article coated with the composition according to claim 1 .

20. A method of treating and/or preventing a disease or disorder in a human or animal patient, the method comprising administering the pharmaceutical composition according to claim 15 .

Assignees

• Ecole Polytechnique Fed Lausanne Epfl

Inventors

• Gerber Sandrine
• Passemard Solene
• Wandrey Christine
• Buhler Leo
• Morel Philippe

Classifications

• C08J2471/02

  Polyalkylene oxides · CPC title

• C08J2305/04

  Alginic acid; Derivatives thereof · CPC title

• A61K9/5036

  Polysaccharides, e.g. gums, alginate; Cyclodextrin · CPC title

• A61K9/06 Primary

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• C08L5/08

  Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title